Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Direct cost of health care for individuals with community associated Clostridium difficile infections: A population-based cohort study.

Singh H, Nugent Z, Walkty A, Yu BN, Lix LM, Targownik LE, Bernstein CN, Witt J.

PLoS One. 2019 Nov 8;14(11):e0224609. doi: 10.1371/journal.pone.0224609. eCollection 2019.

2.

Answer to November 2019 Photo Quiz.

Walkty A, Karlowsky J, Embil J.

J Clin Microbiol. 2019 Oct 23;57(11). pii: e01394-18. doi: 10.1128/JCM.01394-18. Print 2019 Nov. No abstract available.

PMID:
31645415
3.

Photo Quiz: A 59-Year-Old Male with Nodular Cutaneous Lesions.

Walkty A, Karlowsky J, Embil J.

J Clin Microbiol. 2019 Oct 23;57(11). pii: e01393-18. doi: 10.1128/JCM.01393-18. Print 2019 Nov. No abstract available.

PMID:
31645414
4.

An 81-year-old Male With a Pulsatile Abdominal Mass.

Walkty A, Koulack J, Milligan B, Lu M, Mottola J, Embil J.

Clin Infect Dis. 2019 Sep 27;69(8):1456-1459. doi: 10.1093/cid/ciy996. No abstract available.

PMID:
31559438
5.

Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16.

Lagacé-Wiens PRS, Adam HJ, Poutanen S, Baxter MR, Denisuik AJ, Golden AR, Nichol KA, Walkty A, Karlowsky JA, Mulvey MR, Golding G, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv22-iv31. doi: 10.1093/jac/dkz284.

PMID:
31505648
6.

Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study.

McCracken MG, Adam HJ, Blondeau JM, Walkty AJ, Karlowsky JA, Hoban DJ, Zhanel GG, Mulvey MR; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv32-iv38. doi: 10.1093/jac/dkz285.

PMID:
31505643
7.

42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study.

Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Golden AR, Hink R, Lagacé-Wiens PRS, Walkty A, Mulvey MR, Schweizer F, Bay D, Hoban DJ, Karlowsky JA; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv5-iv21. doi: 10.1093/jac/dkz283.

PMID:
31505641
8.

In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016.

Karlowsky JA, Lagacé-Wiens PRS, Adam HJ, Baxter MR, Laing NM, Walkty AJ, Zhanel GG.

Int J Antimicrob Agents. 2019 Jul;54(1):62-68. doi: 10.1016/j.ijantimicag.2019.04.012. Epub 2019 Apr 26.

PMID:
31034938
9.

Lemierre's Syndrome.

Walkty A, Embil J.

N Engl J Med. 2019 Mar 21;380(12):e16. doi: 10.1056/NEJMicm1808378. No abstract available.

10.

Report of a KPC-producing Pseudomonas aeruginosa isolate in Canada.

Walkty A, Alexander DC, Karlowsky JA, Nichol K, Embil J.

J Antimicrob Chemother. 2019 Jun 1;74(6):1748-1749. doi: 10.1093/jac/dkz064. No abstract available.

PMID:
30783655
11.

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.

Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Review.

PMID:
30712199
12.

Frequency of 16S ribosomal RNA methyltransferase detection among Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013-2017).

Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Boyd D, Bharat A, Mulvey MR, Charles M, Bergevin M, Zhanel GG.

Diagn Microbiol Infect Dis. 2019 Jun;94(2):199-201. doi: 10.1016/j.diagmicrobio.2018.12.005. Epub 2018 Dec 14.

PMID:
30638654
13.

Anaplasmosis: An emerging tick-borne disease of importance in Canada.

Uminski K, Kadkhoda K, Houston BL, Lopez A, MacKenzie LJ, Lindsay R, Walkty A, Embil J, Zarychanski R.

IDCases. 2018 Nov 28;14:e00472. doi: 10.1016/j.idcr.2018.e00472. eCollection 2018.

14.

Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study.

Denisuik AJ, Garbutt LA, Golden AR, Adam HJ, Baxter M, Nichol KA, Lagacé-Wiens P, Walkty AJ, Karlowsky JA, Hoban DJ, Mulvey MR, Zhanel GG.

J Antimicrob Chemother. 2019 Mar 1;74(3):645-653. doi: 10.1093/jac/dky477.

PMID:
30500898
15.

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli.

Karlowsky JA, Adam HJ, Baxter MR, Denisuik AJ, Lagacé-Wiens PRS, Walkty AJ, Puttagunta S, Dunne MW, Zhanel GG.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01832-18. doi: 10.1128/AAC.01832-18. Print 2019 Jan.

16.

In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study.

Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Zhanel GG.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e02068-18. doi: 10.1128/AAC.02068-18. Print 2019 Jan.

17.

Failure of a multiplex polymerase chain reaction assay to detect IMP-27 in a clinical isolate of Morganella morganii.

Walkty A, Adam H, Tran V, Alexander DC, Boyd D, Bharat A, Karlowsky J.

Diagn Microbiol Infect Dis. 2018 Nov;92(3):194-195. doi: 10.1016/j.diagmicrobio.2018.06.011. Epub 2018 Jun 22.

PMID:
30025967
18.

Evaluation of three MALDI-TOF mass spectrometry libraries for the identification of filamentous fungi in three clinical microbiology laboratories in Manitoba, Canada.

Stein M, Tran V, Nichol KA, Lagacé-Wiens P, Pieroni P, Adam HJ, Turenne C, Walkty AJ, Normand AC, Hendrickx M, Piarroux R, Karlowsky JA.

Mycoses. 2018 Oct;61(10):743-753. doi: 10.1111/myc.12800. Epub 2018 Jul 2.

PMID:
29893421
19.

Disseminated Mycobacterium bovis infection post-kidney transplant following remote intravesical BCG therapy for bladder cancer.

Ziegler J, Ho J, Gibson IW, Nayak JG, Stein M, Walkty A, Orr P.

Transpl Infect Dis. 2018 Oct;20(5):e12931. doi: 10.1111/tid.12931. Epub 2018 Jun 13.

PMID:
29809299
20.

Correction to: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2018 May;78(7):787. doi: 10.1007/s40265-018-0910-x.

PMID:
29748749
21.

Jamestown Canyon virus meningoencephalitis mimicking migraine with aura in a resident of Manitoba.

Vosoughi R, Walkty A, Drebot MA, Kadkhoda K.

CMAJ. 2018 Mar 5;190(9):E262-E264. doi: 10.1503/cmaj.170940. No abstract available.

22.

Case Report: A Case of Colorado Tick Fever Acquired in Southwestern Saskatchewan.

Kadkhoda K, Semus M, Jelic T, Walkty A.

Am J Trop Med Hyg. 2018 Mar;98(3):891-893. doi: 10.4269/ajtmh.17-0761. Epub 2018 Jan 18.

23.

In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.

Walkty A, Adam H, Baxter M, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2018 Mar 1;73(3):703-708. doi: 10.1093/jac/dkx468.

PMID:
29244121
24.

Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9. Review. Erratum in: Drugs. 2018 May 10;:.

PMID:
29230684
25.

Central nervous system blastomycosis diagnosed using the MVista® Blastomyces quantitative antigen enzyme immunoassay test on cerebrospinal fluid: A case report and review of the literature.

Walkty A, Keynan Y, Karlowsky J, Dhaliwal P, Embil J.

Diagn Microbiol Infect Dis. 2018 Feb;90(2):102-104. doi: 10.1016/j.diagmicrobio.2017.10.015. Epub 2017 Oct 31. Review.

PMID:
29195765
26.

Marked peripheral eosinophilia due to prolonged administration of posaconazole.

Alharbi M, Jhinger RK, Wuerz T, Walkty A.

JMM Case Rep. 2017 Jun 30;4(6):e005100. doi: 10.1099/jmmcr.0.005100. eCollection 2017 Jun.

27.

Antimicrobial susceptibility of 2906 Pseudomonasaeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015.

Walkty A, Lagace-Wiens P, Adam H, Baxter M, Karlowsky J, Mulvey MR, McCracken M, Zhanel GG.

Diagn Microbiol Infect Dis. 2017 Jan;87(1):60-63. doi: 10.1016/j.diagmicrobio.2016.10.003. Epub 2016 Oct 7.

PMID:
28336136
28.

In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.

Karlowsky JA, Walkty AJ, Baxter MR, Arhin FF, Moeck G, Adam HJ, Zhanel GG.

Diagn Microbiol Infect Dis. 2017 Apr;87(4):349-356. doi: 10.1016/j.diagmicrobio.2017.01.006. Epub 2017 Jan 20.

PMID:
28159446
29.

Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015).

Walkty A, Karlowsky JA, Adam HJ, Lagacé-Wiens P, Baxter M, Mulvey MR, McCracken M, Poutanen SM, Roscoe D, Zhanel GG.

CMAJ Open. 2016 Oct 26;4(4):E641-E645. doi: 10.9778/cmajo.20160080. eCollection 2016 Oct-Dec.

30.

Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.

Zhanel GG, Hartel E, Adam H, Zelenitsky S, Zhanel MA, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty AJ, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2016 Dec;76(18):1737-1757. Review.

PMID:
27909995
31.

Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis.

Zhanel GG, Walkty AJ, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2016;2016:2082693. doi: 10.1155/2016/2082693. Epub 2016 May 10. Review.

32.

Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.

Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty A, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2016 Apr;76(5):567-88. doi: 10.1007/s40265-016-0545-8. Review.

PMID:
26863149
33.

Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.

Zhanel GG, Walkty AJ, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2015 Nov-Dec;26(6):305-12. Review.

34.

Empyema caused by Clostridium bifermentans: A case report.

Edagiz S, Lagace-Wiens P, Embil J, Karlowsky J, Walkty A.

Can J Infect Dis Med Microbiol. 2015 Mar-Apr;26(2):105-7.

35.

In vitro activity of ceftazidime-avibactam against 338 molecularly characterized gentamicin-nonsusceptible Gram-negative clinical isolates obtained from patients in Canadian hospitals.

Denisuik AJ, Karlowsky JA, Denisuik T, Nichols WW, Keating TA, Adam HJ, Baxter M, Walkty A, Zhanel GG.

Antimicrob Agents Chemother. 2015;59(6):3623-6. doi: 10.1128/AAC.00364-15. Epub 2015 Mar 30.

36.

Isolation of multiple carbapenemase-producing Gram-negative bacilli from a patient recently hospitalized in Nigeria.

Walkty A, Gilmour M, Simner P, Embil JM, Boyd D, Mulvey M, Karlowsky J.

Diagn Microbiol Infect Dis. 2015 Apr;81(4):296-8. doi: 10.1016/j.diagmicrobio.2015.01.005. Epub 2015 Jan 19.

PMID:
25676712
37.

Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.

Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F, Gorityala B, Lagacé-Wiens PR, Rubinstein E, Walkty A, Gin AS, Gilmour M, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2015 Feb;75(3):253-70. doi: 10.1007/s40265-015-0352-7. Review.

PMID:
25673021
38.

In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.

Karlowsky JA, Walkty AJ, Baxter MR, Adam HJ, Zhanel GG.

Diagn Microbiol Infect Dis. 2014 Dec;80(4):311-5. doi: 10.1016/j.diagmicrobio.2014.09.003. Epub 2014 Sep 16.

PMID:
25294303
39.

Osteomyelitis due to multiple carbapenemase-producing Gram-negative bacteria: The first case report of a GES-13-producing Pseudomonas aeruginosa isolate in Canada.

Sepehri S, Poliquin G, Alfattoh N, Boyd D, Mulvey M, Denisuik A, Fanella S, Karlowsky J, Walkty A.

Can J Infect Dis Med Microbiol. 2014 Jul;25(4):229-31.

40.

An unusual case of Streptococcus anginosus group pyomyositis diagnosed using direct 16S ribosomal DNA sequencing.

Walkty A, Embil JM, Nichol K, Karlowsky J.

Can J Infect Dis Med Microbiol. 2014 Spring;25(1):32-4.

41.

In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.

Walkty A, Adam H, Baxter M, Denisuik A, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2014 May;58(5):2554-63. doi: 10.1128/AAC.02744-13. Epub 2014 Feb 18.

42.

Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.

Lagacé-Wiens P, Walkty A, Karlowsky JA.

Core Evid. 2014 Jan 24;9:13-25. doi: 10.2147/CE.S40698. eCollection 2014. Review.

43.

Evaluation of MRSASelect (™) chromogenic medium for the early detection of methicillin-resistant Staphylococcus aureus from blood cultures.

Manickam K, Walkty A, Lagacé-Wiens PR, Adam H, Swan B, McAdam B, Pieroni P, Alfa M, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2013 Winter;24(4):e113-6.

44.

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2. Review.

PMID:
24352909
45.

In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.

Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PR, Walkty AJ, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2013 Nov;57(11):5600-11. doi: 10.1128/AAC.01485-13. Epub 2013 Aug 26.

46.

In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.

Walkty A, Karlowsky JA, Adam H, Baxter M, Lagacé-Wiens P, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2013 Nov;57(11):5707-9. doi: 10.1128/AAC.01404-13. Epub 2013 Aug 12.

47.

Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study.

Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Lagacé-Wiens PR, Walkty A, Karlowsky JA, Schweizer F, Hoban DJ; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i7-22. doi: 10.1093/jac/dkt022.

PMID:
23587781
48.

Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11.

Lagacé-Wiens PR, Adam HJ, Low DE, Blondeau JM, Baxter MR, Denisuik AJ, Nichol KA, Walkty A, Karlowsky JA, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i23-9. doi: 10.1093/jac/dkt023.

PMID:
23587775
49.

Caulobacter species as a cause of postneurosurgical bacterial meningitis in a pediatric patient.

Bridger N, Walkty A, Crockett M, Fanella S, Nichol K, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2012 Spring;23(1):e10-2.

50.

Evaluation of an algorithmic approach in comparison with the Illumigene assay for laboratory diagnosis of Clostridium difficile infection.

Walkty A, Lagacé-Wiens PR, Manickam K, Adam H, Pieroni P, Hoban D, Karlowsky JA, Alfa M.

J Clin Microbiol. 2013 Apr;51(4):1152-7. doi: 10.1128/JCM.03203-12. Epub 2013 Jan 30.

Supplemental Content

Loading ...
Support Center